PMS2 and colorectal carcinoma: For CRC, cumulative lifetime risks by age 75 are estimated at 46% for path_MLH1, 43% for path_MSH2, and 15% for path_MSH6 carriers, with MLH1 and MSH2 carriers showing significantly higher risks (40%–70%) compared to MSH6 and PMS2 heterozygotes (10%–20%) [35].